Generic name: mycophenolic acid
Dosage form: tablet, delayed release
This dosage information does not include all the information needed to use Myfortic safely and effectively. See full prescribing information for Myfortic.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
The recommended dose of Myfortic® (mycophenolic acid) is 720 mg administered twice daily (1440 mg total daily dose) on an empty stomach, one hour before or two hours after food intake (see CLINICAL PHARMACOLOGY, Food Effect).
Myfortic delayed-release tablets and mycophenolate mofetil (MMF) tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent.
Patients are to be instructed that Myfortic tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating.
Pediatric: Based on a pharmacokinetic study conducted in stable renal pediatric transplant patients, the recommended dose of Myfortic in stable pediatric patients is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily). Patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Myfortic 180 mg tablets or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Myfortic 180 mg tablets or two Myfortic 360 mg tablets twice daily (1440 mg daily dose). Pediatric doses for patients with BSA <1.19 m2 cannot be accurately administered using currently available formulations of Myfortic tablets.
Geriatrics: The maximum recommended dose is 720 mg administered twice daily.
Treatment During Rejection Episodes
Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Myfortic is not required.
Patients with Renal Impairment
No dose adjustments are needed in patients experiencing delayed renal graft function postoperatively. Patients with severe chronic renal impairment (GFR <25 mL/min/1.73 m2 BSA) should be carefully followed for potential adverse reactions due to increase in free MPA and total MPAG concentrations (see CLINICAL PHARMACOLOGY, Pharmacokinetics: Special Populations).